Published in Ther Drug Monit on April 01, 2009
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol (2014) 1.38
Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation (2011) 1.29
Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol (2011) 1.29
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet Genomics (2012) 1.21
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther (2015) 1.20
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients-A Prospective, Randomized Study. Transplantation (2015) 1.19
Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog (2013) 1.04
Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation (2013) 1.03
Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol (2011) 1.02
Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol (2011) 1.00
Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics (2012) 0.94
Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study. Eur J Clin Pharmacol (2011) 0.92
Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J Proteome Res (2010) 0.90
Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PLoS One (2014) 0.90
PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics (2013) 0.89
Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol (2013) 0.88
Manic-like psychosis associated with elevated trough tacrolimus blood concentrations 17 years after kidney transplant. Case Rep Psychiatry (2013) 0.85
African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients. Pharmacotherapy (2015) 0.85
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenet Genomics (2010) 0.82
Validation of an LC-MS/MS method to determine five immunosuppressants with deuterated internal standards including MPA. BMC Clin Pharmacol (2012) 0.82
The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opin Drug Metab Toxicol (2011) 0.82
ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS One (2014) 0.81
BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression. J Transplant (2011) 0.81
Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use. Drug Des Devel Ther (2015) 0.81
Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. Eur J Hosp Pharm Sci Pract (2013) 0.81
Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation. Eur J Clin Pharmacol (2014) 0.80
Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica (2015) 0.80
The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation. Br J Pharmacol (2012) 0.80
Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol (2013) 0.80
Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients. Acta Pharmacol Sin (2011) 0.79
External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol (2016) 0.79
Pathophysiological idiosyncrasies and pharmacokinetic realities may interfere with tacrolimus dose titration in liver transplantation. Eur J Clin Pharmacol (2011) 0.78
Therapeutic drug monitoring in pediatric renal transplantation. Pediatr Nephrol (2014) 0.78
Role of pharmacogenomics in dialysis and transplantation. Curr Opin Nephrol Hypertens (2014) 0.78
Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients. Eur J Clin Pharmacol (2014) 0.78
Dose increase needed in most cystic fibrosis lung transplantation patients when changing from twice- to once-daily tacrolimus oral administration. Eur J Clin Pharmacol (2015) 0.77
Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation. Int J Mol Sci (2015) 0.77
Variations in Practice to Therapeutic Monitoring of Tacrolimus following Primary Adult Liver Transplantation. Int J Organ Transplant Med (2016) 0.77
Comparison between ultra-performance liquid chromatography with tandem mass spectrometry and a chemiluminescence immunoassay in the determination of cyclosporin A and tacrolimus levels in whole blood. Exp Ther Med (2013) 0.77
Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients. Eur J Clin Pharmacol (2011) 0.77
A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. Clin Pharmacokinet (2017) 0.76
Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol (2013) 0.76
Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. Clin Pharmacokinet (2016) 0.75
Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation. Br J Clin Pharmacol (2013) 0.75
Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation. Int J Clin Exp Med (2015) 0.75
Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. AAPS J (2014) 0.75
Application of Machine-Learning Models to Predict Tacrolimus Stable Dose in Renal Transplant Recipients. Sci Rep (2017) 0.75
Cognitive Evaluation in Liver Transplant Patients Under Calcineurin Inhibitor Maintenance Therapy. Transplant Direct (2017) 0.75
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. Br J Clin Pharmacol (2014) 0.75
Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS. Bioanalysis (2015) 0.75
Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique. Eur J Clin Pharmacol (2015) 0.75
Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients. Clin Pharmacokinet (2017) 0.75
Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol (2012) 0.75
Intrarenal resistive index after renal transplantation. N Engl J Med (2013) 4.19
Collapse, reported seizure--and an unexpected pill. Lancet (2007) 3.25
Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol (2013) 2.85
Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J Am Coll Cardiol (2007) 2.56
Henoch-Schönlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol (2002) 2.44
Measurement of the integral refractive index and dynamic cell morphometry of living cells with digital holographic microscopy. Opt Express (2005) 2.40
Cell refractive index tomography by digital holographic microscopy. Opt Lett (2006) 2.19
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics (2004) 2.06
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med (2006) 1.97
Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem (2005) 1.96
Living specimen tomography by digital holographic microscopy: morphometry of testate amoeba. Opt Express (2006) 1.94
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol (2003) 1.93
Kidney transplant in black recipients: are African Europeans different from African Americans? Am J Transplant (2005) 1.88
Minimally invasive video-assisted thyroidectomy: multiinstitutional experience. World J Surg (2002) 1.80
Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int (2004) 1.78
Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum (2010) 1.75
Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant (2004) 1.75
Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int (2011) 1.73
Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int (2008) 1.71
Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int (2010) 1.71
The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant (2004) 1.69
KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. J Clin Invest (2015) 1.69
p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol (2010) 1.66
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem (2011) 1.64
Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychother Psychosom (2014) 1.64
Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology (2008) 1.62
Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J (2005) 1.58
Acute barium intoxication and hemodiafiltration. J Toxicol Clin Toxicol (2003) 1.55
Bartter's and Gitelman's syndromes: from gene to clinic. Nephron Physiol (2004) 1.54
Simultaneous cell morphometry and refractive index measurement with dual-wavelength digital holographic microscopy and dye-enhanced dispersion of perfusion medium. Opt Lett (2008) 1.53
Autophagy protects renal tubular cells against cyclosporine toxicity. Autophagy (2008) 1.53
ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest (2013) 1.52
Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr Transplant (2003) 1.52
Determination of lowest possible creatinine in living-donor kidney renal transplant recipients based on donor kidney function. Transplantation (2008) 1.50
Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant (2004) 1.48
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity (2008) 1.48
cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. Transplantation (2004) 1.48
Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem (2013) 1.48
Automated segmentation of multiple red blood cells with digital holographic microscopy. J Biomed Opt (2013) 1.47
Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila) (2010) 1.47
Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol (2010) 1.46
Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem (2003) 1.45
Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation. J Surg Res (2012) 1.45
Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. Transplantation (2010) 1.45
Adverse health effects of child labor: high exposure to chromium and oxidative DNA damage in children manufacturing surgical instruments. Environ Health Perspect (2012) 1.44
Cidofovir may be deleterious in BK virus-associated nephropathy. Transplantation (2010) 1.41
Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine. Lab Invest (2009) 1.40
Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients. Transplantation (2011) 1.39
Re: Drugs, driving and sobriety tests. J Clin Forensic Med (2003) 1.38
Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol (2011) 1.38
The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol (2002) 1.38
Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant (2004) 1.38
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood (2009) 1.37
Early cell death detection with digital holographic microscopy. PLoS One (2012) 1.35
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant (2003) 1.34
In vivo endoscopic tissue diagnostics based on spectroscopic absorption, scattering, and phase function properties. J Biomed Opt (2003) 1.34
Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation (2008) 1.34
Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation (2002) 1.33
Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol (2010) 1.33
Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant (2007) 1.30
Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit (2006) 1.30
Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis (2004) 1.28
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics (2011) 1.27
Noninvasive characterization of the fission yeast cell cycle by monitoring dry mass with digital holographic microscopy. J Biomed Opt (2009) 1.26
Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation (2005) 1.24
Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem (2002) 1.23
Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant (2002) 1.23
The place of liver transplantation in Caroli's disease and syndrome. Transpl Int (2006) 1.23
Associations of urinary cadmium with age and urinary proteins: further evidence of physiological variations unrelated to metal accumulation and toxicity. Environ Health Perspect (2013) 1.22
CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics (2013) 1.21
Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation (2005) 1.21
Confounders in the assessment of the renal effects associated with low-level urinary cadmium: an analysis in industrial workers. Environ Health (2011) 1.21
Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet (2009) 1.21
Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol (2010) 1.21
Comparative study of human erythrocytes by digital holographic microscopy, confocal microscopy, and impedance volume analyzer. Cytometry A (2008) 1.20
Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther (2002) 1.20
Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med (2010) 1.17
Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. Ther Drug Monit (2007) 1.17
Internet-based virtual classroom and educational management software enhance students' didactic and clinical experiences in perfusion education programs. J Extra Corpor Technol (2004) 1.16
Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos (2004) 1.15
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem (2005) 1.14
A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma. Dermatology (2007) 1.13